Searched for: in-biosketch:yes
person:morgag04
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
Melchor, L; Brioli, A; Wardell, C P; Murison, A; Potter, N E; Kaiser, M F; Fryer, R A; Johnson, D C; Begum, D B; Hulkki Wilson, S; Vijayaraghavan, G; Titley, I; Cavo, M; Davies, F E; Walker, B A; Morgan, G J
Although intratumor heterogeneity has been inferred in multiple myeloma (MM), little is known about its subclonal phylogeny. To describe such phylogenetic trees in a series of patients with MM, we perform whole-exome sequencing and single-cell genetic analysis. Our results demonstrate that at presentation myeloma is composed of two to six different major clones, which are related by linear and branching phylogenies. Remarkably, the earliest myeloma-initiating clones, some of which only had the initiating t(11;14), were still present at low frequencies at the time of diagnosis. For the first time in myeloma, we demonstrate parallel evolution whereby two independent clones activate the RAS/MAPK pathway through RAS mutations and give rise subsequently to distinct subclonal lineages. We also report the co-occurrence of RAS and interferon regulatory factor 4 (IRF4) p.K123R mutations in 4% of myeloma patients. Lastly, we describe the fluctuations of myeloma subclonal architecture in a patient analyzed at presentation and relapse and in NOD/SCID-IL2Rγ(null) xenografts, revealing clonal extinction and the emergence of new clones that acquire additional mutations. This study confirms that myeloma subclones exhibit different survival properties during treatment or mouse engraftment. We conclude that clonal diversity combined with varying selective pressures is the essential foundation for tumor progression and treatment resistance in myeloma.
PMID: 24480973
ISSN: 1476-5551
CID: 3694962
Current and potential epigenetic targets in multiple myeloma
Pawlyn, Charlotte; Kaiser, Martin F; Davies, Faith E; Morgan, Gareth J
Despite recent advances in therapy, subgroups of multiple myeloma continue to have a poor prognosis. Numerous epigenetic changes have been described and occur as both etiologic and secondary events, making myeloma a good disease in which to understand the role of epigenetic therapies. Here, we describe a number of current and potential epigenetic targets in myeloma.
PMID: 24811790
ISSN: 1750-192x
CID: 3648412
Biology and treatment of myeloma
Brioli, Annamaria; Melchor, Lorenzo; Walker, Brian A; Davies, Faith E; Morgan, Gareth J
In recent years significant progress has been made in the understanding of multiple myeloma (MM) biology and its treatment. Current strategies for the treatment of MM involve the concept of sequential blocks of therapy given as an induction followed by consolidation and maintenance. In an age characterized by emerging and more powerful laboratory techniques, it is of primary importance to understand the biology of MM and how this biology can guide the development of new treatment strategies. This review focuses on the genetic basis of myeloma, including the most common genetic abnormalities and pathways affected and the effects that these have on MM treatment strategies. MM biology is discussed also in the light of more recent theory of intraclonal heterogeneity.
PMID: 25486959
ISSN: 2152-2669
CID: 3648522
The genetic and epigenetic mechanisms underlying the behavior of myeloma
Chapter by: Kaiser, Martin F.; Boyd, Kevin D.; Morgan, Gareth J.
in: MYELOMA: PATHOLOGY, DIAGNOSIS, AND TREATMENT by ; Schey, SA; Yong, KL; Marcus, R; Anderson, KC
CAMBRIDGE : CAMBRIDGE UNIV PRESS, 2014
pp. 48-63
ISBN: 978-1-107-01057-4
CID: 3647112
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
Walker, Brian A; Wardell, Christopher P; Melchor, Lorenzo; Brioli, Annamaria; Johnson, David C; Kaiser, Martin F; Mirabella, Fabio; Lopez-Corral, Lucia; Humphray, Sean; Murray, Lisa; Ross, Mark; Bentley, David; Gutiérrez, Norma C; Garcia-Sanz, Ramón; San Miguel, Jesus; Davies, Faith E; Gonzalez, David; Morgan, Gareth J
The mechanisms involved in the progression from monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) to malignant multiple myeloma (MM) and plasma cell leukemia (PCL) are poorly understood but believed to involve the sequential acquisition of genetic hits. We performed exome and whole-genome sequencing on a series of MGUS (n=4), high-risk (HR)SMM (n=4), MM (n=26) and PCL (n=2) samples, including four cases who transformed from HR-SMM to MM, to determine the genetic factors that drive progression of disease. The pattern and number of non-synonymous mutations show that the MGUS disease stage is less genetically complex than MM, and HR-SMM is similar to presenting MM. Intraclonal heterogeneity is present at all stages and using cases of HR-SMM, which transformed to MM, we show that intraclonal heterogeneity is a typical feature of the disease. At the HR-SMM stage of disease, the majority of the genetic changes necessary to give rise to MM are already present. These data suggest that clonal progression is the key feature of transformation of HR-SMM to MM and as such the invasive clinically predominant clone typical of MM is already present at the SMM stage and would be amenable to therapeutic intervention at that stage.
PMCID:3916874
PMID: 23817176
ISSN: 1476-5551
CID: 3649542
Haematological cancer: Optimizing the treatment of multiple myeloma
Morgan, Gareth J; van Rhee, Frits
PMID: 25348792
ISSN: 1759-4782
CID: 3648492
Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment [Letter]
Pawlyn, Charlotte; Khan, Mohid S; Muls, Ann; Sriskandarajah, Priya; Kaiser, Martin F; Davies, Faith E; Morgan, Gareth J; Andreyev, H Jervoise N
PMID: 25301337
ISSN: 1528-0020
CID: 3648482
Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice
Landgren, Ola; Morgan, Gareth J
Since the mid-1990s, the multiple myeloma treatment landscape has evolved considerably, which has led to improved patient outcomes and prolonged survival. In addition to discovering new, targeted agents or treatment regimens, the identification and validation of biomarkers has the potential to further improve patient outcomes. The International Staging System relies on a number of biochemical parameters to stratify patients into risk categories. Other biologically relevant markers that are indicative of inherited genetic variation (e.g., single-nucleotide polymorphisms) or tumor-acquired genetic events (e.g., chromosomal translocations or mutations) have been studied for their prognostic potential. In patients with high-risk cytogenetics, plasma cells (PC) undergo genetic shifts over time, which may partially explain why high-risk patients relapse and are so difficult to treat. Although novel agents have improved treatment outcomes, identification of markers that will enable clinicians to determine which treatment is most appropriate for high-risk patients following initial diagnosis represents an exciting frontier in the clinical management of multiple myeloma. Biomarkers based on quantitating PCs or factors that are secreted from them (e.g., serum free light chain) may also help to risk-stratify patients with asymptomatic multiple myeloma. Eventually, identification of novel biomarkers may lead to the creation of personalized treatment regimens that are optimized to target clonal PCs that express a specific oncogenomic profile. Although the future is exciting, validation will be necessary before these biologic and molecular beacons can inform decision-making processes in a routine clinical setting.
PMCID:5576179
PMID: 24270684
ISSN: 1078-0432
CID: 3648282
Curing myeloma at last: defining criteria and providing the evidence
Barlogie, Bart; Mitchell, Alan; van Rhee, Frits; Epstein, Joshua; Morgan, Gareth J; Crowley, John
Does the dogma that multiple myeloma is incurable still hold?. The genomic chaos and resulting resistance to apoptosis of myeloma, long considered an obstacle to cure, formed the basis of Total Therapy (TT) program. The TT approach uses all myeloma-active drugs upfront to target drug-resistant subclones during initial treatment to prevent later relapse. Long-term follow-up of 1202 patients (TT1: n = 231, median follow-up: 21 years; TT2: 668, median follow-up: 12 years; TT3a: n = 303, median follow-up: 9 years) permitted investigation of whether progression-free survival (PFS) and complete response (CR) duration were consistent with curability, ie observation of plateaus in Kaplan-Meier plots for PFS and CR duration. In the subset of 627 patients with plasma cell gene expression profiling data, cure plateaus were apparent at 5 years in the 14% with high-risk myeloma compared with 10 years in the remainder with low-risk disease. A parametric model based on PFS and CR duration supported an increase in curability: 10-year PFS and CR estimates increased from 8.8%/17.9% in TT1 to 15.5%/28.2% in TT2's control arm to 25.1%/35.6% in TT2's thalidomide arm and to 32.9%/48.8% in TT3a. Toward developing novel therapies, we recommend a concerted focus on patients with high-risk myeloma whose outcome has not been advanced.
PMCID:4231416
PMID: 25293776
ISSN: 1528-0020
CID: 3648472
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
Brioli, Annamaria; Giles, Hannah; Pawlyn, Charlotte; Campbell, John P; Kaiser, Martin F; Melchor, Lorenzo; Jackson, Graham H; Gregory, Walter M; Owen, Roger G; Child, J Anthony; Davies, Faith E; Cavo, Michele; Drayson, Mark T; Morgan, Gareth J
Intraclonal heterogeneity was recently described in multiple myeloma (MM), but its full impact on disease progression and relapse has not been entirely explored. The immunoglobulin type produced by myeloma cells provides an excellent marker to follow changes in clonal substructure over time. We have prospectively evaluated serial paraprotein and serum free light chain (FLC) measurements and found that 258 of 520 and 54 of 520 patients who presented with a whole paraprotein relapsed with paraprotein only (PO) and "FLC escape," respectively. The median overall survival of PO patients was longer, when compared with patients whose relapse manifested as an increase in FLC both alone and with a whole paraprotein, as a result of a significantly shorter survival from relapse of the latter groups. These observations fit a model in which 1 clone is able to produce a complete antibody, whereas the other secretes only FLC; the type of relapse represents the outgrowth of different clones, some of which are more resistant to therapy. To our knowledge, this is the largest series describing patients who have relapsed with FLC escape and highlights the importance of monitoring FLC when there is a suspicion of clinical relapse. This study was registered at www.isrctn.org as ISRCTN68454111.
PMID: 24733348
ISSN: 1528-0020
CID: 3648382